<DOC>
	<DOCNO>NCT01498497</DOCNO>
	<brief_summary>This purpose study long-term follow-up glucocorticosteroid-related adverse event hypothalamic-pituitary-adrenal axis ( HPA ) suppression subject discontinuation study drug receive PR-021 study ( Safety Tolerability Study Oral EUR-1100 Treat Eosinophilic Esophagitis ) . The study also provide opportunity well understand natural course eosinophilic esophagitis define treatment modality eosinophilic esophagitis EUR-1100 , need chronic maintenance intermittent treatment . All subject complete PR-021 offer opportunity participate study . The duration follow-up study six month , subject visit clinic safety evaluation clinical symptom assessment screening , Week 8 , Week 16 , Week 24 visit . Additional phone visit occur Week 4 , Week 12 , Week 20 .</brief_summary>
	<brief_title>A Six Month , Safety Follow-up Study Eosinophilic Esophagitis Subjects Who Completed Study PR-021</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Subject complete full participation Study PR021 ( Subjects discontinue prematurely PR021 due HPA axis suppression eligible study PR022 ) Written inform consent ( parent legal guardian must sign applicable ) assent form , require Willing able adhere study procedure Subjects already require medication procedure treatment EoE time enrollment followup study , systemic ( oral parenteral ) inhale corticosteroid , esophageal dilation , Proton Pump Inhibitors ( PPIs ) and/or dietary restriction ; case subject already PPIs /or dietary restriction Study PR021 , subject require increase dosage PPIs and/or new dietary restriction worsen symptom exclude Any physical , mental , social condition , history concurrent illness laboratory abnormality , investigator 's judgment , might interfere study procedure ability subject adhere complete study Contraindication esophagogastroduodenoscopy ( EGD ) esophageal biopsy narrow esophagus preclude EGD Female subject pregnant breastfeed Participation clinical study involve investigational drug investigational device</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>